Gastroenterology · 4 h ago
MRI Biomarkers for MASLD Risk Stratification and Treatment Response
This review examines MRI-based biomarkers for diagnosing and monitoring metabolic dysfunction-associated steatotic liver disease (MASLD). It summarizes proposed thresholds for liver fat and stiffness, prognostic associations, composite scores, and potential uses in clinical trials and treatment decisions.
- MRI-PDFF quantifies steatosis; a 30% reduction is associated with histologic response.
- MRE stiffness thresholds are linked to fibrosis stage and decompensation risk.
- Iron-corrected T1 is sensitive but nonspecific; prognostic value remains uncertain.
Liver biopsy remains an invasive, sampling-sensitive reference standard for metabolic dysfunction-associated steatotic liver disease (MASLD). This review summarizes evidence on MRI-based biomarkers as noninvasive tools for whole-liver assessment, risk stratification, and evaluation of treatment response; it does not report a new clinical study or sample size.
MRI proton density fat fraction (MRI-PDFF) is described as the most accurate noninvasive measure of steatosis, with thresholds of 6.4%, 17.4%, and 22.1% for grades 1 or higher, 2 or higher, and grade 3, respectively. A relative MRI-PDFF reduction of at least 30% is associated with histologic response. Magnetic resonance elastography liver stiffness of 3.1–4.4 kPa corresponds to F2–F3 fibrosis, while values of at least 5 kPa correspond to cirrhosis; each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation.
The review also discusses iron-corrected T1, composite scores, and artificial intelligence applications. Iron-corrected T1 is sensitive but nonspecific, and its prognostic value needs further study. These imaging measures may support assessment and research, but the source does not establish that they should replace biopsy or independently determine treatment decisions.
In practice
For clinicians assessing adults with MASLD, the review describes MRI-PDFF as a quantitative measure of steatosis and MRE liver stiffness as an imaging marker associated with fibrosis stage and hepatic decompensation risk. A relative MRI-PDFF reduction of at least 30% is associated with histologic response, but this is not itself proof of clinical benefit. The review does not establish that MRI can replace biopsy or that these thresholds should independently guide therapy; iron-corrected T1 remains nonspecific and its prognostic value requires further study.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Hepatology: MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.